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Abstract
Background: The purpose of this study was to determine the dosimetric effect of on-line position
correction for bladder tumor irradiation and to find methods to predict and handle this effect.
Methods: For 25 patients with unifocal bladder cancer intensity modulated radiotherapy (IMRT)
with 5 beams was planned. The requirement for each plan was that 99% of the target volume
received 95% of the prescribed dose. Tumor displacements from -2.0 cm to 2.0 cm in each
dimension were simulated, using 0.5 cm increments, resulting in 729 simulations per patient. We
assumed that on-line correction for the tumor was applied perfectly. We determined the
correlation between the change in D99% and the change in path length, which is defined here as the
distance from the skin to the isocenter for each beam. In addition the margin needed to avoid
underdosage was determined and the probability that an underdosage occurs in a real treatment
was calculated.
Results: Adjustments for tumor displacement with perfect on-line position correction resulted in
an altered dose distribution. The altered fraction dose to the target varied from 91.9% to 100.4%
of the prescribed dose. The mean D99% (± SD) was 95.8% ± 1.0%. There was a modest linear
correlation between the difference in D99% and the change in path length of the beams after
correction (R2 = 0.590). The median probability that a systematic underdosage occurs in a real
treatment was 0.23% (range: 0 - 24.5%). A margin of 2 mm reduced that probability to < 0.001% in
all patients.
Conclusion: On-line position correction does result in an altered target coverage, due to changes
in average path length after position correction. An extra margin can be added to prevent
underdosage.
Background
External beam radiotherapy is a common treatment for
muscle-invasive bladder cancer for patients unfit or
unwilling to undergo a radical cystectomy. Unifocality of
the tumor allows irradiation of only the tumor and to
spare the healthy part of the bladder, or to give the tumor
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giving the healthy bladder a prophylactic dose [1,2]. How-
ever, the position of a bladder tumor varies markedly day-
to-day, up to several centimeters, due to bladder and
bowel movements and bladder filling [3-8]. For radiother-
apy, large margins are necessary to compensate for this
uncertainty, resulting in a high dose to the surrounding
healthy tissue. The probability of serious complications in
the healthy tissue limits the dose that can be administered
to the tumor. Since bladder tumors move independently
of the bones, a portal image of the pelvic bones is not suit-
able for determining the current position of a bladder
tumor [5].
Fortunately, the possibilities for image guided radiother-
apy (IGRT) have increased substantially in the last decade
and a megavoltage image of the bony anatomy is no
longer the only option. The recent development of a cone-
beam CT (CBCT) mounted on the linear accelerator ena-
bles in-room soft-tissue visualization [9]. However, the
soft-tissue contrast is poor and to visualize the bladder
tumor effectively markers have to be inserted around the
tumor. The combination of CBCT and implanted markers
opens up the way for on-line position correction of blad-
der tumors [10,11]. This technique enables margin reduc-
tion, leading to a decreased risk of healthy tissue
complications and it might enable dose escalation.
Applying on-line position correction causes beams to pass
through a different amount of tissue and through differ-
ent tissue types compared to the treatment plan, resulting
in an altered attenuation for these beams (figure 1). The
question arises: how is the target dose distribution
affected by these differences in attenuation with respect to
the treatment plan?
Similarly, an effect of on-line position correction on the
target dose for the prostate has been reported [12-14]. Sev-
eral authors studied the target coverage of the prostate
after applying translational position correction. They con-
cluded that on average the target dose after position cor-
rection is higher than without correction, but lower than
in the treatment plan. All studies explained the remaining
underdosage by rotations that were not included in the
correction and by deformations. Van Herten et al. have
shown that when there is no correction for rotations, the
target coverage of the prostate is still 98.7% and for the
seminal vesicles 95.7%, even though the planning was
done without PTV margin [15]. Orton and Tomé
neglected rotations of the prostate and they found that the
dose distribution after applying position correction was
nearly identical to the treatment plan [16].
However, the prostate is located relatively central with
respect to the body contour, while bladder tumors can
also be present on the ventral side of the bladder. This
might have a considerable effect on the dose distribution
when the tumor moves. In addition, the typical day-to-
day variation in the position of a bladder tumor is larger
than that of the prostate. Therefore the above mentioned
results do not automatically apply for on-line position
correction for bladder cancer.
In this study we investigated the effect of on-line position
correction for bladder tumors on the dose distribution.
The goal of this study was to determine what the effect of
on-line position correction of bladder tumors is on the
dose distribution, how it can be predicted and how it can
be handled. In order to put the results into perspective, we
added the results of the analysis of tumor movement in
recently treated bladder cancer patients in our depart-
ment.
Methods
Patients
This study included 25 patients with a histologically
proven bladder tumor who were previously treated in our
department. For all patients a planning CT with 3 mm
slices was acquired with the patient in the supine position.
The tumor was delineated by an experienced radiation
oncologist. The average tumor volume was 48.8 cc (range:
7.4 - 116.0 cc). The delineated tumor volume was used as
the clinical target volume (CTV) [17]. Bladder and rectum
were also delineated. Because we wanted to investigate the
effect of on-line position correction only and were not
Schematic representation of a simulationFigure 1
Schematic representation of a simulation. The black 
target and beam axes represent the treatment plan. Grey 
represents the situation on a particular treatment day. The 
tumor has moved within the body and position correction is 
applied to ensure that the beams are at the same location 
with respect to the target.Page 2 of 8
(page number not for citation purposes)
Radiation Oncology 2009, 4:38 http://www.ro-journal.com/content/4/1/38interested in all other uncertainties and errors, we did not
use a CTV-PTV margin in this simulation study.
Treatment planning
IMRT plans with five beams were generated for each
patient: 40°, 110°, 180°, 250° and 320°. We used
PLATO (Nucletron BV, Veenendaal, the Netherlands) for
treatment planning. The dose calculation was based on
Bortfeld's pencil beam algorithm [18] and we corrected
for inhomogeneities, using an improved version of the
equivalent tissue-air ratio (ETAR) correction [19]. The
requirement of the plans was that 99% of the volume of
the CTV was covered by the 95% isodose. This plan was
only generated for study purposes. The patients were actu-
ally treated with our current technique and a CTV-PTV
margin [1,17].
Simulation
The treatment plan was made with the tumor in the orig-
inal position as outlined on the planning CT. In the sim-
ulation the tumor was shifted to another position and
perfect position correction was applied, i.e. the beam
positions were kept constant with respect to the target.
This is schematically represented in figure 1. All other
parameters, for example the beam geometry and the
number of monitor units, were kept constant. We simu-
lated shifts from -2.0 to 2.0 cm in 0.5 cm increments in
the left-right, cranial-caudal and dorsal-ventral direction
and all combinations, yielding 93 = 729 shifts. The dose
distribution was calculated for each shift. A stand-alone
version of PLATO's dose engine was used for these com-
putations. This PC version of PLATO was highly opti-
mized for fast dose calculations on a graphical card [20].
Analysis
The dose at least received by 99% of the volume (D99%) of
the CTV was evaluated. If the D99% was lower than 95%, it
was considered an underdosage. Differences in the dose
distribution are caused by changes in path length and to a
lesser degree by changes in tissue type. The SSD of beams
might change, as can be seen in figure 1, and the beams
may pass through bone which they did not in the treat-
ment plan, or vice versa. We investigated the correlation
between the dose and the average path length of the five
beams, using SPSS 16.0.2. (SPSS Inc., Chicago, USA).
Both the dose and the path length were calculated relative
to the treatment plan in order to evaluate the results for all
patients at once. We calculated the linear regression of
dose versus path length for the results of all patients.
A distinction was made between the physical path length
(PPL) and the radiological path length (RPL). By physical
path length we mean the path length from the skin to the
isocenter for the central beam axis in centimeters. The
radiological path length is this length corrected for the rel-
ative electron density and it represents the equivalent path
length in water.
Besides calculating the average path length of the five
beams of each simulation, the physical path length
weighted over the number of monitor units of each beam
(PPLMU) was also determined:
where PPLi is the physical path length of beam i and MUi
is the number of MUs of beam i and n is the number of
beams. The radiological path length weighted over the
number of MUs per beam (RPLMU) was calculated by sub-
stituting RPL for PPL in equation 1. The correlation coef-
ficient was used to determine which of the four predictors
(PPL, RPL, PPLMU or RPLMU) was the best predictor of the
dose change at the target.
Margin
We investigated what margin was needed to have avoided
underdosage despite perfect position correction in the two
'worst case' patients from our data analysis, i.e. the two
patients with the lowest D99% in a single fraction. An iso-
tropic CTV-PTV margin of 2 mm was used. New IMRT
plans were made with this margin and the full simulation
was repeated for these patients. If this margin was not suf-
ficient, the margin was increased by 1 mm increments and
the planning and simulation were repeated until a satis-
factory margin was obtained.
Analysis of tumor movement and probability of 
underdosage
In order to calculate the probabilities of each shift to occur
in an actual treatment, the movement of the bladder
tumor in recently treated bladder cancer patients in our
department was determined. The displacement of the
tumor with respect to the bones was analyzed in patients
with implanted markers from whom at least 6 CBCTs
were available. These data were supplemented with the
data of patients without markers, but with at least 6 repeat
CTs. For the latter group the tumor was delineated in each
repeat CT and the displacement of the center of gravity
(CoG) of the tumor with respect to the bony anatomy was
analyzed. Because the image quality of the CBCT is not
sufficient for delineation, we could only use patients with
enough (at least 6) regular CTs for the group without
markers. We determined the systematic and random com-
ponent of the tumor movement with respect to the bones.
For that purpose, we first determined the individual mean
and standard deviation for each patient, using translations
PPL
PPLi*MUi
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tematic component of the tumor movement in all
patients is the SD of the individual means and the random
component is the root mean square of the individual SDs.
Based on these tumor displacement data, the probability
that a systematic underdosage occurred was calculated for
each patient. First, the probability that a simulated shift
could be the systematic displacement of a real treatment
was calculated. Next we determined for each patient
which shifts resulted in an underdosage. The probability
of all shifts that led to an underdosage were summed for
each patient, which gave the probability that a systematic
underdosage occurred. Note that we did only simulate the
effect of systematic errors, not that of additional random
errors.
From the tumor displacement data the margin that would
be necessary if no position correction was applied can also
be determined, using Van Herk's margin recipe [21]:
where m is the margin, Σ the systematic tumor displace-
ment and σ the random tumor displacement. This margin
was compared to the margin that was needed when on-
line position correction was applied.
Results
Dose
When the tumor was displaced with respect to the body
contour and position correction was applied perfectly, the
dose distribution changed with respect to the treatment
plan. These changes showed up both in the magnitude of
D99% as well as in the shape of the 95% isodose. Note that
this could also imply a dose increase. Figure 2 shows an
example of the dose distribution in a treatment plan and
the dose distribution when the tumor has moved 2.0 cm
in the dorsal direction. In general, the dose increased
when the tumor moved in the caudal and ventral direc-
tions and the dose decreased when the tumor moved in
the cranial and dorsal directions (figure 3). The result of
displacement in the left-right direction was patient-
dependent, probably dependent on the location of the
tumor on the bladder wall.
The D99% was at least 95% of the prescribed dose in 75.5%
of all the simulated situations and at least 94% of the pre-
scribed dose in 95.2% of the simulations (figure 4). The
lowest D99% observed in all simulations was 91.9%, the
highest was 100.4% and the mean D99% (± SD) was 95.8%
± 1.0%.
Correlation between dose and path length
The correlation coefficient R2 was 0.51 (p < 0.001), 0.25
(p < 0.001), 0.59 (p < 0.001) and 0.25 (p < 0.001) for the
correlation for all patients between dose and PPL, RPL,
PPLMU and RPLMU, respectively. Figure 5a shows the result
of the relative dose difference and PPLMU for all patients.
One patient, denoted patient P, had aberrant results; the
slope of the regression curve was 1.22, whereas the mean
slope (± SD) of the other individual regression curves was
-2.39 ± 1.53. When patient P was excluded from the anal-
ysis, R2 = 0.67 (p < 0.001) for the correlation between dose
and PPLMU (fig 5b).
Margin
Additional treatment plans with small margins were made
for the two worst case patients and the simulation was
repeated. The result of replanning with an increased mar-
gin was an increase of the minimum dose to the tumor,
also in the treatment plan. For the worst patient a margin
of 3 mm was necessary to avoid underdosage and for the
other patient a margin of 2 mm was sufficient.
Analysis of tumor movement and probability of 
underdosage
We determined the systematic and random components
of the tumor movement with respect to the bony anatomy
in each direction. For five patients the CBCTs were ana-
lyzed, with an average of 7.8 scans per patient. For 16
patients the regular CTs were analyzed, with an average of
mPTV = +2 5 0 7. . ,S s (2)
Dose distribution at the targetFigure 2
Dose distribution at the target. (a) Planning situation. (b) 
Situation when the tumor moved 2 cm dorsal and the patient 
position was corrected. After position correction the result-
ing dose is lower and shaped differently compared to the 
treatment plan of this scenario.
a
b
100%  of 
prescribed 
dose
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(left-right), ΣDV (dorsal-ventral) and ΣCC (cranial-caudal)
were 1.8 mm, 4.7 mm and 4.1 mm, respectively. Random
displacement σLR, σDV and σCC were 1.7 mm, 3.4 mm and
3.5 mm, respectively. If no position correction would be
applied a margin of 5.7 mm, 14.2 mm and 12.7 mm in
the left-right, dorsal-ventral and cranial-caudal direction,
respectively, would be needed to compensate for tumor
displacement, using Van Herk's margin recipe [21].
With the above SDs of systematic tumor displacement, we
calculated the probability of a systematic underdosage
(i.e., a D99% lower than 95% of the prescribed dose) if no
margin was applied for each patient. When no margin was
applied, the median of this probability was only 0.23%.
For 16 out of the 25 patients this probability was below
1%, for 8 patients the probability was between 1% and
14% and one patient had a probability of 24.5%. The
probability of a D99% below 94% was 0.07% in the worst
case patient and smaller than 0.01% in all other cases.
When a margin of 2 mm was applied, the probability of a
D99% lower than 95% was smaller than 0.001% in the one
patient for whom 2 mm was not sufficient for all simu-
lated shifts.
Discussion
The goal of this study was to investigate whether under-
dosage still occurs with perfect on-line position correction
and if so, under what conditions it occurs and how it can
be dealt with. We have shown that even if on-line position
correction is applied perfectly, underdosage can still
occur. There was a linear correlation between the dose dif-
ference and the change in averaged path length of the
beams. A margin can be added to prevent this underdos-
age.
Although the tumor is underdosed in some situations, the
lowest D99% that occurred in this study was still 91.9%.
This represents the worst case of all 18225 simulations
and was calculated for a shift of 2 cm cranially, 2 cm dor-
sally and 2 cm to the left. However, this result is much bet-
ter than not applying position correction at all. With the
systematic displacement of the tumor that we found in
our patients, it is highly unlikely that this will be the sys-
tematic error of a treatment.
For every patient we calculated what the probability was
that a systematic underdosage occurred in a real treat-
ment. The range of probabilities that were found is large,
0-24.5%, but in most cases that probability is small and
the median is 0.23%. The probability that the dose is sys-
tematically below 94% is 0.07% in the worst case and
smaller than 0.01% in all other cases.
In this study we focused on D99% and every result below
95% was considered an underdosage, but for the clinical
D99% over the dorsal and ventral axesFigure 3
D99% over the dorsal and ventral axes. Values of D99% 
for all shifts over the dorsal-ventral and cranial-caudal axes 
averaged over all patients. The X-axis represents tumor dis-
placement in the dorsal-ventral direction and the Y-axis the 
cranial-caudal direction. There is no shift in the left-right axis 
in this case. The dose increases when the tumor moves in 
the caudal and ventral direction. The dose decreases when 
the tumor moves in the cranial and dorsal direction.
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Tomé and Fowler found in a modelling study that an
underdosage in a subvolume as small as 1% of the volume
of the tumor can already decrease the tumor control prob-
ability (TCP) [22]. However, this TCP decrease was appar-
ent only if the dose in that subvolume was more than 10%
lower than the prescribed dose. With a minimal D99% of
91.9% a decrease in TCP is not likely in our study.
Overdosage, on the other hand, might be a risk too,
because constraints for organs at risk (OARs) can be vio-
lated. However, the dose increases when the tumor moves
in the ventral and caudal direction, while the OARs - the
rectum and small intestines - are located on the dorsal and
cranial side of the bladder, respectively.
The change in dose with respect to the treatment plan can
be predicted using the number of MUs per beam and the
change in physical path length. Considering the radiolog-
ical path length of the central axis only is apparently not
the best predictor for dose differences, although this
might seem counterintuitive. A likely explanation is that
the central axis ray of each beam is not representative of
the change in radiological path length of the entire beam.
The correlation between weighted path length and dose
did not hold for one of the 25 patients: patient P. A more
detailed analysis of patient P showed that the tumor was
highly elongated. When the dose in one part of the tumor
increased as expected, the dose in another part of the
tumor decreased, causing an overall decrease in D99%. In
general the change in path length is a good predictor for
the change in dose, but in practice its applicability will be
limited.
It would be interesting to perform a similar study with
daily CBCTs and investigate how large the dose difference
over the whole treatment is with the real body contour
and tumor position. Presently, not enough daily CBCTs
are available in our institution to perform such an analy-
sis. Furthermore, we cannot delineate the tumor on the
CBCT, because of the poor image quality caused by scat-
ter. The position of the tumor can be found using the
markers, but in the case of deformation the shape cannot
be determined. Another problem related to the scatter is
that we cannot rely on the CBCT for dose calculation,
because the grey values of the CBCT do not correspond to
those of the CT. Moreover, the grey values are also related
to the size of the patient and therefore it is hard to assign
correct electron densities to the hounsfield units. Recent
studies have shown that the errors in dose calculation for
CBCT decrease from 10-20% to 1-2% when correction
techniques are applied, which is very promising for future
dose calculation for CBCT [23,24].
Without on-line position correction a margin of 5.7 mm
left-right, 14.2 mm dorsal-ventral and 12.7 mm in the cra-
nial-caudal direction would be needed to compensate for
tumor displacement. This is sufficient to ensure that 90%
of the patient population receives a dose of 95% or higher
in the CTV. When on-line position correction is used, a
margin of 2 mm would be sufficient in more than 99.99%
of the patients. However, margins are not only meant for
Correlation difference D99% and path length changeFigure 5
Correlation difference D99% and path length change. a: The results of all simulations of all 25 patients with respect to 
the treatment plan. On the X-axis is the difference in path length weighted with MUs (PPLMU) with respect to the treatment 
planning and on the Y-axis is the difference in dose with respect to the treatment plan. b: The results when patient P is 
excluded.
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Radiation Oncology 2009, 4:38 http://www.ro-journal.com/content/4/1/38compensation of target translations, but they are also
needed for uncertainties that cannot be corrected by on-
line position correction for translations, such as deforma-
tions, rotations, intrafraction motion and delineation
uncertainties. Because we only wanted to study the effect
of on-line position correction all these errors were
ignored, but they should not be forgotten in clinical prac-
tice. Engels et al. have already shown a reduced treatment
outcome for patients with implanted markers and daily
positioning and they also warn not to reduce margins too
much [25].
The minimal D99% in this study was 91.9%, which is not
that much lower than the required 95%. Furthermore, it is
highly unlikely that the lowest D99% of this study will
occur in a real patient. The modelling study of Tomé and
Fowler suggests that our minimal D99% will not reduce the
TCP [22]. We therefore recommend not to increase the
margins to compensate for underdosage due to path
length changes. Note that all other uncertainties should
be adequately covered.
Conclusion
The purpose of this study was to investigate the dosimetric
effect of on-line position correction. The conclusion is
that the dose distribution changes with respect to the
treatment plan, even if the target is not deformed and does
not rotate. However, the occurring underdosage is small,
D99% is 91.9% in the worst case. The probability that an
underdosage occurs in an actual treatment is small for
most patients, but with a large spread: median 0.23%,
range 0-24.5%. With a margin of 2 mm, the probability of
underdosage is < 0.001% for all patients.
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